LAUREN PANY: Open Payments
NPI 1942845631 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,364 in 79 payments from 13 companies in 2025. Trend: 2023 $1,081 · 2024 $985 · 2025 $1,364
Food & beverage: $1,253Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $411 |
| Alkermes, Inc. | 16 | $233 |
| Otsuka America Pharmaceutical, Inc. | 9 | $151 |
| Neurocrine BioSciences, Inc. | 15 | $143 |
| Janssen Pharmaceuticals, Inc | 4 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $80 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| ABBVIE INC. | 2 | $47 |
| Lundbeck LLC | 2 | $36 |
| Almatica Pharma LLC | 2 | $31 |
Products named: AUSTEDO XR, REXULTI, INGREZZA, ARISTADA, INVEGA SUSTENNA, LYBALVI, CAPLYTA, UZEDY.
Industry payments across PA — which companies pay providers there.
